Pharmacological Applications of Bile Acids and Their Derivatives in the Treatment of Metabolic Syndrome
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Apart from well-known functions of bile acids in digestion and solubilization of lipophilic nutrients and drugs in the small intestine, the emerging evidence from the past two decades identified the role of bile acids as signaling, endocrine molecules that regulate the glucose, lipid, and energy metabolism through complex and intertwined pathways that are largely mediated by activation of nuclear receptor farnesoid X receptor (FXR) and cell surface G protein-coupled receptor 1, TGR5 (also known as GPBAR1). Interactions of bile acids with the gut microbiota that result in the altered composition of circulating and intestinal bile acids pool, gut microbiota composition and modified signaling pathways, are further extending the complexity of biological functions of these steroid derivatives. Thus, bile acids signaling pathways have become attractive targets for the treatment of various metabolic diseases and metabolic syndrome opening the new potential avenue in their treatment. In addition, there is a significant effort to unveil some specific properties of bile acids relevant to their intrinsic potency and selectivity for particular receptors and to design novel modulators of these receptors with improved pharmacokinetic and pharmacodynamic profiles. This resulted in synthesis of few semi-synthetic bile acids derivatives such as 6α-ethyl-chenodeoxycholic acid (obeticholic acid, OCA), norursodeoxycholic acid (norUDCA), and 12-monoketocholic acid (12-MKC) that are proven to have positive effect in metabolic and hepato-biliary disorders. This review presents an overview of the current knowledge related to bile acids implications in glucose, lipid and energy metabolism, as well as a potential application of bile acids in metabolic syndrome treatment with future perspectives.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
A comprehensive review on metabolic syndrome
Kaur, J. (2014) · Cardiology Research and Practice · doi:10.1155/2014/943162 · Cited by 1,889
RetractedNeuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis
Jia, W., Xie, G., & Jia, W. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.119 · Cited by 1,924 · cited 1×
“The most hydrophobic bile acid, based on chromatographic behavior is LCA, followed by DCA, CDCA, CA and UDCA (Jia et al., 2017).”
BackgroundTGR5-Mediated Bile Acid Sensing Controls Glucose Homeostasis
Thomas, C., Gioiello, A., Noriega, L., Strehle, A., Oury, J., Rizzo, G., Macchiarulo, A., Yamamoto, H., Mataki, C., Pruzanski, M., et al. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.08.001 · Cited by 1,885
Prevalence of the metabolic syndrome in the United States, 2003-2012
Aguilar, M., Bhuket, T., Torres, S., Liu, B., & Wong, R. J. (2015) · JAMA · doi:10.1001/jama.2015.4260 · Cited by 1,267
Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor
Inagaki, T., Moschetta, A., Lee, Y.-K., Peng, L., Zhao, G., Downes, M., Yu, R. T., Shelton, J. M., Richardson, J. A., Repa, J. J., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509592103 · Cited by 1,164 · cited 1×
“Besides, bile acids can modulate gut microbiota composition both, directly, by destroying the structures of bacterial membranes, and indirectly, via FXR activation by promoting the transcription of antimicrobial agents such as iNOS and IL-18 in the small intestine and thereby inhibiting bacterial growth (Inagaki et al…”
BackgroundA Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
Nevens, F., Andreone, P., Mazzella, G., Strasser, S. I., Bowlus, C., Invernizzi, P., Drenth, J. P. H., Pockros, P. J., Regula, J., Beuers, U., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509840 · Cited by 1,131
Current Understanding of Dysbiosis in Disease in Human and Animal Models
DeGruttola, A. K., Low, D., Mizoguchi, A., & Mizoguchi, E. (2016) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000750 · Cited by 1,122
Identification of membrane-type receptor for bile acids (M-BAR)
Maruyama, T., Miyamoto, Y., Nakamura, T., Tamai, Y., Okada, H., Sugiyama, E., Nakamura, T., Itadani, H., & Tanaka, K. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)02550-0 · Cited by 993
Chávez-Talavera, O., Tailleux, A., Lefebvre, P., & Staels, B. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.01.055 · Cited by 970
Mudaliar, S., Henry, R. R., Sanyal, A. J., Morrow, L., Marschall, H., Kipnes, M., Adorini, L., Sciacca, C. I., Clopton, P., Castelloe, E., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.05.042 · Cited by 931
FXR is a molecular target for the effects of vertical sleeve gastrectomy
Ryan, K. K., Tremaroli, V., Clemmensen, C., Kovatcheva-Datchary, P., Myronovych, A., Karns, R., Wilson-Pérez, H. E., Sandoval, D. A., Kohli, R., Bäckhed, F., et al. (2014) · Nature · doi:10.1038/nature13135 · Cited by 931
Katsuma, S., Hirasawa, A., & Tsujimoto, G. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.01.139 · Cited by 789
Paumgartner, G., & Beuers, U. (2002) · Hepatology · doi:10.1053/jhep.2002.36088 · Cited by 748
Pellicciari, R., Fiorucci, S., Camaioni, E., Clerici, C., Costantino, G., Maloney, P. R., Morelli, A., Parks, D. J., & Willson, T. M. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm025529g · Cited by 743 · cited 2×
“…only obeticholic acid (OCA, 6-ethyl-chenodeoxycholic acid, 6-ECDCA INT-747) has currently been clinically useful and approved as a potent and specific FXR agonist with 100-fold higher affinity compared to the CDCA – endogenous FXR agonist with the highest potency (Pellicciari et al., 2002).”
BackgroundIntestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance
Fang, S., Suh, J. M., Reilly, S. M., Yu, E., Osborn, O., Lackey, D., Yoshihara, E., Perino, A., Jacinto, S., Lukasheva, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3760 · Cited by 738
Bile-acid-induced cell injury and protection
Perez, M. J., & Briz, O. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.1677 · Cited by 717
Beneficial metabolic effects of a probiotic via butyrate-induced GLP-1 hormone secretion
Yadav, H., Lee, J.-H., Lloyd, J., Walter, P., & Rane, S. G. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.452516 · Cited by 709
Bile acids as regulatory molecules
Hylemon, P. B., Zhou, H., Pandak, W. M., Ren, S., Gil, G., & Dent, P. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r900007-jlr200 · Cited by 694 · cited 1×
“Over the past decade, a growing body of evidence has strongly indicated that bile acids regulate glycemic postprandial metabolism displaying also anti-diabetic signaling capacities by acting through bile acid-activating receptors, as well as by improving protein folding and function, in addition to antiapoptotic effec…”
BackgroundComponents of the “Metabolic Syndrome” and Incidence of Type 2 Diabetes
Hanson, R. L., Imperatore, G., Bennett, P. H., & Knowler, W. C. (2002) · Diabetes · doi:10.2337/diabetes.51.10.3120 · Cited by 590
Hirschfield, G. M., Mason, A., Luketic, V., Lindor, K., Gordon, S. C., Mayo, M., Kowdley, K. V., Vincent, C., Bodhenheimer, H. C., Parés, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.12.005 · Cited by 576 · cited 1×
“During the same year, FDA gave approval for the use of semi-synthetic potent and selective FXR agonist, OCA, for primary biliary cirrhosis therapy in patients with unsatisfactory response to UDCA administration as a monotherapy (Hirschfield et al., 2015).”
BackgroundHuman Insulin Resistance Is Associated With Increased Plasma Levels of 12α-Hydroxylated Bile Acids
Haeusler, R. A., Astiarraga, B., Camastra, S., Accili, D., & Ferrannini, E. (2013) · Diabetes · doi:10.2337/db13-0639 · Cited by 444
Pournaras, D. J., Glicksman, C., Vincent, R. P., Kuganolipava, S., Alaghband-Zadeh, J., Mahon, D., Bekker, J. H. R., Ghatei, M. A., Bloom, S. R., Walters, J. R. F., et al. (2012) · Endocrinology · doi:10.1210/en.2011-2145 · Cited by 383
Salehi, M., Prigeon, R. L., & D’Alessio, D. A. (2011) · Diabetes · doi:10.2337/db11-0203 · Cited by 323 · cited 1×
“Beneficial effects mediated by the bile acid receptors FXR and TGR5 following bariatric surgery were further confirmed since in the absence of FXR signaling in FXR-null mice or antagonizing GLP-1 signaling by exendin-(9-39), the beneficial effects of bariatric surgery on body weight and glucose metabolism were abolish…”
BackgroundnorUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis
Fickert, P., Hirschfield, G. M., Denk, G., Marschall, H.-U., Altorjay, I., Färkkilä, M., Schramm, C., Spengler, U., Chapman, R., Bergquist, A., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.05.009 · Cited by 297
Bile acid signaling pathways from the enterohepatic circulation to the central nervous system
Mertens, K. L., Kalsbeek, A., Soeters, M. R., & Eggink, H. M. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00617 · Cited by 287
Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis
Adorini, L., Pruzanski, M., & Shapiro, D. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.05.012 · Cited by 259 · cited 1×
“During preclinical studies OCA administration had significant beneficial effects in numerous disorders of enterohepatic system including improvement of estrogen-induced cholestasis, liver fibrosis, NASH, insulin signaling, portal hypertension, reduction of intestinal inflammation and improvement of ileal barrier funct…”
BackgroundVerbeke, L., Farre, R., Trebicka, J., Komuta, M., Roskams, T., Klein, S., Elst, I. V., Windmolders, P., Vanuytsel, T., Nevens, F., et al. (2014) · Hepatology · doi:10.1002/hep.26939 · Cited by 258
The Role of Bile Acids in Glucose Metabolism and Their Relation with Diabetes
Alberto González-Regueiro, J., Moreno-Castañeda, L., Uribe, M., & Carlos Chávez-Tapia, N. (2017) · Annals of Hepatology · doi:10.5604/01.3001.0010.5494 · Cited by 247
Gastric bypass and banding equally improve insulin sensitivity and β cell function
Bradley, D., Conte, C., Mittendorfer, B., Eagon, J. C., Varela, J. E., Fabbrini, E., Gastaldelli, A., Chambers, K. T., Su, X., Okunade, A., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci64895 · Cited by 244
Obesity and Cardiac Remodeling in Adults: Mechanisms and Clinical Implications
Alpert, M. A., Karthikeyan, K., Abdullah, O., & Ghadban, R. (2018) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2018.07.012 · Cited by 221 · cited 1×
“Obesity is also associated with hemodynamic alterations and arterial hypertension which contribute to cardiac morphology changes predisposing to impairment of ventricular function and heart failure (Alpert et al., 2018).”
BackgroundKumar, D. P., Rajagopal, S., Mahavadi, S., Mirshahi, F., Grider, J. R., Murthy, K. S., & Sanyal, A. J. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.09.104 · Cited by 206 · cited 1×
“…intestinal GLP-1 secretion from entero-endocrine L cells, both in vitro and in vivo, stimulating the release of insulin from the pancreatic β-cells without the release of glucagon from α-cells, and reducing postprandial glycaemia (Katsuma et al., 2005; Kumar et al., 2012; Duboc et al., 2014).”
BackgroundNuclear receptors in bile acid metabolism
Li, T., & Chiang, J. Y. L. (2013) · Drug Metabolism Reviews · doi:10.3109/03602532.2012.740048 · Cited by 176 · cited 1×
“The accumulation of bile acids during cholestasis and subsequent activation of CAR reduces hepatocellular injury by the reduction of bile acid synthesis as well as by inducing metabolizing enzymes and transporter proteins, which mediates removal of hydrophobic bile acids from hepatocytes (Li and Chiang, 2013; Gabbia e…”
BackgroundFarnesoid x receptor ligands inhibit vascular smooth muscle cell inflammation and migration
Li, Y. T. Y., Swales, K. E., Thomas, G. J., Warner, T. D., & Bishop-Bailey, D. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.152694 · Cited by 171
Nonalcoholic fatty liver disease – current status and future directions
Demir, M., Lang, S., & Steffen, H. (2015) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12291 · Cited by 105
Tauroursodeoxycholic acid improves motor symptoms in a mouse model of Parkinson's disease
Rosa, A. I., Duarte-Silva, S., Silva-Fernandes, A., Nunes, M. J., Carvalho, A. N., Rodrigues, E., Gama, M. J., Rodrigues, C. M. P., Maciel, P., & Castro-Caldas, M. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1062-4 · Cited by 94 · cited 1×
“This is particularly relevant for tauro-UDCA which has proven beneficial therapeutic effect in central nervous system in models of Parkinson’s disease, neuroinflammation, retinal degenerative diseases, spinal cord injury (Lobysheva et al., 2018; Miao et al., 2018; Rosa et al., 2018).”
BackgroundRole of bile acids in the regulation of the metabolic pathways
Taoka, H., Yokoyama, Y., Morimoto, K., Kitamura, N., Tanigaki, T., Takashina, Y., Tsubota, K., & Watanabe, M. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i13.260 · Cited by 80
Cited by
Gut microbiota-derived metabolites as central regulators in metabolic disorders
Agus, A., Clément, K., & Sokol, H. (2021) · Gut · doi:10.1136/gutjnl-2020-323071 · Cited by 1,347
“39 BAs also impact lipid metabolism, especially by exerting profound effects on triacylglycerol.”
BackgroundBile acids and the gut microbiota: metabolic interactions and impacts on disease
Collins, S. L., Stine, J. G., Bisanz, J. E., Okafor, C. D., & Patterson, A. D. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00805-x · Cited by 1,214
Functions of Gut Microbiota Metabolites, Current Status and Future Perspectives
Liu, J., Tan, Y., Cheng, H., Zhang, D., Feng, W., & Peng, C. (2022) · Aging and disease · doi:10.14336/ad.2022.0104 · Cited by 529
“is linked to a series of diseases such as obesity, T2DM, dyslipidemia, nonalcoholic fatty liver disease, atherosclerosis, and heart failure [109-112].”
BackgroundBile acid metabolism and signaling, the microbiota, and metabolic disease
Cai, J., Rimal, B., Jiang, C., Chiang, J. Y. L., & Patterson, A. D. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108238 · Cited by 497
García-Montero, C., Fraile-Martínez, O., Gómez-Lahoz, A. M., Pekarek, L., Castellanos, A. J., Noguerales-Fraguas, F., Coca, S., Guijarro, L. G., García-Honduvilla, N., Asúnsolo, A., et al. (2021) · Nutrients · doi:10.3390/nu13020699 · Cited by 431
Metadata
- Authors
- Ðanić, M., Stanimirov, B., Pavlović, N., Goločorbin-Kon, S., Al-Salami, H., Stankov, K., & Mikov, M.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2018-12-03
- Volume
- 9
- Pages
- 1382-1382
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W2903438339
- Cited by
- 133
- References
- 37
- FWCI
- 5.31
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.